Clinical outcome after multicenter, open-label phase II trial on post-surgery chemoradiation in combination with cetuximab in squamous cell carcinoma of the head and neck with high risk of locoregional recurrence.

Christiane Matuschek,E. Boelke,Claus Belka,Ute Ganswindt,Michael Henke,P. Stegmaier,M. Bamberg,Stephan Welz,Juergen Debus,Alexandros Gioules,Thomas G. Wendt,Gerd Fabian Volk,Thomas Wiegel,Volker Budach,Martin Stuschke,Peter Arne Gerber,J. Schipper,Juergen Grebe,Wilfried Budach

Clinical outcome after multicenter, open-label phase II trial on post-surgery chemoradiation in combination with cetuximab in squamous cell carcinoma of the head and neck with high risk of locoregional recurrence.

2016

Christiane Matuschek
E. Boelke
Claus Belka
Ute Ganswindt
Michael Henke
P. Stegmaier
M. Bamberg
Stephan Welz
Juergen Debus
Alexandros Gioules
Thomas G. Wendt
Gerd Fabian Volk
Thomas Wiegel
Volker Budach
Martin Stuschke
Peter Arne Gerber
J. Schipper
Juergen Grebe
Wilfried Budach

6028Background: We performed an open label phase 2 trial and investigated the efficacy and toxicity of additional cetuximab during and after adjuvant radiochemotherapy (RCT) in head and neck cancer...

Keywords:

Cetuximab
Carcinoma
Pathology
General surgery
Medicine
Adjuvant
head and neck
Head and neck cancer
open label
Randomized controlled trial
Toxicity
post surgery
Oncology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations